Text Size

Curcumin Bioavailability in Glioblastoma Patients

This study is currently recruiting participants.
Verified October 2012 by Johann Wolfgang Goethe University Hospitals
Sponsor:
Information provided by (Responsible Party):
Stephan Dützmann, Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier:
NCT01712542
First received: October 20, 2012
Last updated: October 22, 2012
Last verified: October 2012
History of Changes
  Purpose

Measuring the bioavailability of orally administered curcumin in the tumors of glioblastoma patients.


Condition Phase
Patient Harboring Glioblastoma That Will Undergo Surgery
 Phase 0

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement of Intratumoral Concentration of the Nontoxic Natural Compound Curcumin in Glioblastoma Patients

Resource links provided by NLM:

Drug Information available for: Curcumin
U.S. FDA Resources

Further study details as provided by Johann Wolfgang Goethe University Hospitals:

Primary Outcome Measures:
  • Concentration of Curcumin in Glioblastoma [ Time Frame: At Tumor resection ] [ Designated as safety issue: No ]
    At the time of surgery


Biospecimen Retention:   Samples Without DNA

Tumor tissue


Estimated Enrollment: 15
Study Start Date: October 2012
Estimated Study Completion Date: October 2014
Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients harboring Glioblastoma

Criteria

Inclusion Criteria:

  • Patients harboring Glioblastoma
  • Patient will undergo surgery

Exclusion Criteria:

  • BMI > 30
  • Liver and Kidney Function so compromised that medication is prescribed
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01712542

Contacts
Contact: Stephan - Duetzmann, M.D. +49-6301 ext 5478 stephan.duetzmann@gmail.com
Contact: Christian - Senft, M.D. Ph.D. +49-6301 ext 5470 c.senft@med.uni-frankfurt.de

Locations
Germany
Department of Neurosurgery, Johann Wolfgang Goethe-University Recruiting
Frankfurt, Hessen, Germany, 60528
Contact: Stephan Duetzmann, M.D.     +49-6301 ext 5478     stephan.duetzmann@gmail.com    
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospitals
Investigators
Principal Investigator: Stephan Duetzmann Goethe University
  More Information

Additional Information:
Related Info  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Stephan Dützmann, M.D., Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov Identifier: NCT01712542     History of Changes
Other Study ID Numbers: JohannWGUH_Curcumin-01
Study First Received: October 20, 2012
Last Updated: October 22, 2012
Health Authority: Regierungspräsidium Darmstadt: Germany

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Curcumin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
 Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 19, 2013